April 22 (Reuters) - Adicet Bio Inc :
* ADICET BIO HIGHLIGHTS PRECLINICAL DATA SUPPORTING IND READINESS FOR ADI-270 IN AN ORAL PRESENTATION AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) 27TH ANNUAL MEETING
* ADICET BIO INC - ADI-270 DEMONSTRATED ENHANCED FUNCTIONAL POTENCY AND RESILIENCE IN TUMOR MICROENVIRONMENT
* ADICET BIO INC - ON TRACK TO FILE AN INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATION FOR ADI-270 IN 2Q 2024
* ADICET BIO INC - PRECLINICAL FINDINGS SHOWED ROBUST ANTI-TUMOR ACTIVITY OF ADI-270 IN MULTIPLE CD70-POSITIVE SOLID AND HEMATOLOGICAL CANCER MODELS
Source text for Eikon: Further company coverage:
(Reuters.Briefs@thomsonreuters.com)
Comments